J Y Min1,2, M R Griffin1,2,3, J Chipman1,4, A J Hackstadt1,4, R A Greevy1,4, C G Grijalva1,2, A M Hung1,3, C L Roumie1,3. 1. Veterans Health Administration Tennessee Valley Healthcare System, Geriatric Research and Education Clinical Centre, HSR&D Centre, Nashville, TN, USA. 2. Department of Health Policy, Vanderbilt University Medical Centre, Nashville, TN, USA. 3. Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA. 4. Department of Biostatistics, Vanderbilt University Medical Centre, Nashville, TN, USA.
Abstract
AIM: To evaluate whether recent low adherence to metformin monotherapy is associated with hypoglycaemia after addition of a sulfonylurea. METHODS: We assembled a retrospective cohort of veterans who filled a new prescription for metformin between 2001 and 2011 and intensified treatment with a sulfonylurea after ≥1 year of metformin use. We calculated metformin adherence from pharmacy data using the proportion of days covered in the 180-day period before intensification. The primary outcome was hypoglycaemia, defined as a hospitalization or emergency department visit for hypoglycaemia or an outpatient blood glucose measurement <3.3 mmol/l in the year following intensification. Cox proportional hazards models were used to compare the risk of hypoglycaemia between participants with low (<80%) and high (≥80%) adherence. Adherence was also modelled as a continuous variable using restricted cubic splines. RESULTS: Of 187 267 participants who initiated metformin monotherapy, 49 424 added a sulfonylurea after ≥1 year. The median (interquartile range) rate of treatment adherence was 87 (50-100)% and 43% had adherence <80%. Hypoglycaemia rates per 1000 person-years were 23.1 (95% CI 21.1-25.4) and 24.5 (95% CI 22.7-26.4) in participants with low and high adherence, respectively (adjusted hazard ratio 0.95, 95% CI 0.84-1.08). The risk of hypoglycaemia was similar across all levels of adherence when adherence was modelled as a continuous variable. CONCLUSIONS: We found no evidence that past low adherence to metformin monotherapy was associated with hypoglycaemia after intensification with a sulfonylurea. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
AIM: To evaluate whether recent low adherence to metformin monotherapy is associated with hypoglycaemia after addition of a sulfonylurea. METHODS: We assembled a retrospective cohort of veterans who filled a new prescription for metformin between 2001 and 2011 and intensified treatment with a sulfonylurea after ≥1 year of metformin use. We calculated metformin adherence from pharmacy data using the proportion of days covered in the 180-day period before intensification. The primary outcome was hypoglycaemia, defined as a hospitalization or emergency department visit for hypoglycaemia or an outpatientblood glucose measurement <3.3 mmol/l in the year following intensification. Cox proportional hazards models were used to compare the risk of hypoglycaemia between participants with low (<80%) and high (≥80%) adherence. Adherence was also modelled as a continuous variable using restricted cubic splines. RESULTS: Of 187 267 participants who initiated metformin monotherapy, 49 424 added a sulfonylurea after ≥1 year. The median (interquartile range) rate of treatment adherence was 87 (50-100)% and 43% had adherence <80%. Hypoglycaemia rates per 1000 person-years were 23.1 (95% CI 21.1-25.4) and 24.5 (95% CI 22.7-26.4) in participants with low and high adherence, respectively (adjusted hazard ratio 0.95, 95% CI 0.84-1.08). The risk of hypoglycaemia was similar across all levels of adherence when adherence was modelled as a continuous variable. CONCLUSIONS: We found no evidence that past low adherence to metformin monotherapy was associated with hypoglycaemia after intensification with a sulfonylurea. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Manel Pladevall; L Keoki Williams; Lisa Ann Potts; George Divine; Hugo Xi; Jennifer Elston Lafata Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Kailin L Hsu; Jeffrey C Fink; Jennifer S Ginsberg; Marni Yoffe; Min Zhan; Wanda Fink; Corinne M Woods; Clarissa J Diamantidis Journal: Am J Kidney Dis Date: 2015-05-13 Impact factor: 8.860
Authors: Bruno Linetzky; Dingfeng Jiang; Martha M Funnell; Bradley H Curtis; William H Polonsky Journal: J Diabetes Date: 2016-08-17 Impact factor: 4.006
Authors: Sudeep Karve; Mario A Cleves; Mark Helm; Teresa J Hudson; Donna S West; Bradley C Martin Journal: Curr Med Res Opin Date: 2009-09 Impact factor: 2.580
Authors: Kimberley Krapek; Kathleen King; Susan S Warren; Karen G George; Dorothy A Caputo; Karen Mihelich; Elizabeth M Holst; Michael B Nichol; Sheng G Shi; Kevin B Livengood; Steve Walden; Teresa J Lubowski Journal: Ann Pharmacother Date: 2004-07-06 Impact factor: 3.154